OncoMatch/Clinical Trials/NCT06926283
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Is NCT06926283 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies DXC008 for prostate cancer.
Treatment: DXC008 — This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Tumor Agnostic
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard treatment
Patients with various solid tumors who have failed standard treatment
Cannot have received: XXX-targeted therapy
Exception: in Phase Ia clinical study only
Prior treatment with XXX-targeted therapy or topoisomerase inhibitors (in Phase Ia clinical study only)
Cannot have received: topoisomerase inhibitor
Exception: in Phase Ia clinical study only
Prior treatment with XXX-targeted therapy or topoisomerase inhibitors (in Phase Ia clinical study only)
Cannot have received: systemic antineoplastic therapy
Have received systemic antineoplastic therapy or investigational product treatment within 28 days or 5 half-lives (whichever is shorter) prior to the first dose
Cannot have received: radiotherapy
have received radiotherapy within 14 days prior to the first dose
Cannot have received: monoclonal antibody
Have received monoclonal antibody treatment within 30 days prior to the first dose
Cannot have received: plasmapheresis
Have undergone plasmapheresis within 14 days prior to the first dose
Cannot have received: systemic corticosteroid (prednisone)
Exception: short-term treatment for prevention of contrast media allergy may be enrolled
treated with prednisone at > 10 mg/day for > 3 consecutive days or equivalent dose of systemic corticosteroids or equivalent anti-inflammatory medication within 14 days prior to the first dose
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L (prior use of G-CSF is allowed, but G-CSF use is not allowed within 7 days prior to the screening laboratory tests). Platelet count ≥100×10^9/L (platelet transfusion is not allowed within 7 days before the screening laboratory tests). HGB ≥ 90 g/L (RBC transfusion or recombinant human erythropoietin use is allowed; RBC transfusion is not allowed within 7 days prior to the screening laboratory tests).
Kidney function
Ccr ≥ 60 mL/min; or creatinine ≤ 1.5 × ULN; urinalysis results show protein urine ≤ 1 +. For subjects with urine protein ≥2+ in urinalysis during the screening period, a 24-hour urine protein quantification should be performed, and those with 24-hour urine protein quantification ≤1 g can be enrolled.
Liver function
Total bilirubin (TBIL) ≤1.5×ULN, except for subjects with congenital bilirubinemia, such as Gilbert syndrome (direct bilirubin ≤1.5×ULN). AST and ALT ≤ 3.0 × ULN. For patients with liver metastases, both AST and ALT ≤5×ULN.
Cardiac function
LVEF≥50%. QTcF interval < 470 msec. No evidence of current clinically significant untreated arrhythmias, no history of myocardial infarct, acute coronary syndrome, coronary angioplasty or stent implantation, or bypass grafting within 6 months before screening. No Class III or IV heart failure (NYHA). Uncontrolled severe hypertension: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg excluded.
Organ function of the subjects must meet the following requirements: [see details above]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06926283 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior XXX-targeted therapy, topoisomerase inhibitor, systemic antineoplastic therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages